
Most workplace, clinical, and forensic urine drug tests use immunoassays — fast, cheap antibody-based screens. They are sensitive but not always specific: the antibody can sometimes bind to molecules that resemble the target compound but aren't it. That's called cross-reactivity, and it's the root cause of essentially all false positives in immunoassay drug screens.
For ketamine specifically, the cross-reactivity pattern is much narrower than for other drugs. Cannabinoid immunoassays, for example, have a long list of cross-reactants (NSAIDs, hemp products, certain protein supplements). Ketamine immunoassays have essentially one well-documented cross-reactant: quetiapine.
Quetiapine (brand name Seroquel) is a second-generation antipsychotic prescribed for schizophrenia, bipolar disorder, and (off-label) insomnia. Multiple clinical case reports — most prominently from clinical chemistry literature in Taiwan and Australia — have documented patients on quetiapine whose urine immunoassays returned ketamine-positive results that were later disproven by GC-MS confirmation.
The mechanism is structural: quetiapine and its metabolite quetiapine sulfoxide share certain ring and nitrogen features with ketamine's arylcyclohexylamine core. The shared features are enough for some immunoassay antibodies to bind both molecules, even though quetiapine is pharmacologically nothing like ketamine.
Clinical implication: if a patient is on quetiapine and produces a positive ketamine immunoassay, do not act on the result without GC-MS or LC-MS/MS confirmation.
In the published literature, no other medications are established to cause ketamine cross-reactivity at clinically relevant levels. A few have been investigated and ruled out:
Lab-specific assay quirks can produce one-off false positives, but those are not a generalizable pattern.
For ketamine specifically: none have been documented to cause false positives.
For other drug panels, the picture is different — and this gets conflated in popular sources. Below is what foods and substances do affect, for reference:
| Substance | Causes false positive for | Causes false positive for ketamine? |
|---|---|---|
| Poppy seeds | Opiates (codeine, morphine) | No |
| Hemp / CBD products | Cannabinoids (THC) | No |
| Quinine (tonic water) | Some opiate / quinolone panels | No |
| Pseudoephedrine | Amphetamines | No |
| NSAIDs (ibuprofen) | Cannabinoids, barbiturates | No |
| Quetiapine (Seroquel) | Ketamine | Yes — well documented |
If you read a generic "common causes of false positive drug tests" article, the substances listed are almost always for other panels, not ketamine.
This distinction is the single most important thing to understand about drug tests:
A positive immunoassay screen alone should never be treated as proof of ketamine use. SAMHSA's mandatory guidelines for federal workplace drug testing explicitly require confirmation testing before reporting a positive result, precisely because immunoassays produce too many false positives to act on alone.
For patients on legitimate prescribed ketamine therapy — through Isha Health or another provider — keep documentation of your prescription. A positive confirmation in that context is not a problem; it just confirms what your prescription explains.
Request confirmatory testing (GC-MS or LC-MS/MS) on the same sample, disclose all medications and supplements you're taking, and ask the lab's medical review officer to evaluate the result in light of those medications. If a confirmatory test rules out the substance, the original screen was a false positive.
Different drug panels have different cross-reactants. Common patterns: poppy seeds → opiate false positives; hemp / CBD → cannabinoid false positives; pseudoephedrine → amphetamine false positives. For ketamine specifically, quetiapine is the only well-documented cause.
Supplements with ephedrine alkaloids, hemp derivatives, or some weight-loss products can trigger cannabinoid or amphetamine panels. Mislabeling and impurity in unregulated supplements increases the risk. None have been documented to interfere with ketamine assays specifically.
Cannabinoid (THC) panels have the most documented cross-reactants — NSAIDs, hemp products, certain over-the-counter medications, and a few prescription drugs. Opiate panels are the second most common, mostly from poppy seeds.
Yes — ketamine and its primary metabolite norketamine will appear on a properly-conducted drug screen and be confirmed by GC-MS or LC-MS/MS. If you are in a ketamine therapy program, keep documentation of your prescription. Many workplace testing programs accept prescribed medications with a medical review officer's review.
Considering ketamine therapy? Isha Health offers physician-led at-home treatment with an 88.8% improvement rate. Check appointment availability.
88.8% of Isha Health patients with moderate-to-severe depression show measurable improvement
Based on 546 patients and 1,900+ validated assessments. See our clinical outcomes →
Stay informed on ketamine therapy
Research updates, clinical insights, and mental health resources — delivered to your inbox.